CD200R1 and acute myeloid leukemia: Recently, a novel IFP designed to convert an inhibitory CD200R stimulus into a CD28 costimulus demonstrated how tuning different IFP domains can drastically alter the therapeutic effects in a preclinical model of acute myeloid leukemia (AML) [26].